EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Augmentation of immunothrombosis as a key mechanism underlying JAK inhibition associated hypercoagulability in rheumatoid arthritis

Paula David, Tom Macleod, Ala Altaie, Yu Shi, Kerem Abacar, Sami Giryes, Gabrielle de Mello Santos, Payal Ganguly, Mark Harland, Chi Wong, Andrew Scarsbrook, Paul Emery und 7 weitere

Annals of the Rheumatic Diseases · 2026

DOI: 10.1016/j.ard.2025.09.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of the Rheumatic Diseases, 2026. Verfasst von Paula David und 18 weiteren Autor:innen. Beteiligte Einrichtung: Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Thrombophilia, Janus Kinase Inhibitors, Venous Thromboembolism. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Leeds Biomedical Research Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Venous thromboembolism (VTE), following Janus kinase inhibitors treatment (JAKi), is poorly understood in rheumatoid arthritis (RA). We investigated whether JAKi augmented immune cell-driven clotting or immunothrombosis in RA. METHODS: Peripheral blood leukocytes (PBLs) isolated from patients with RA and healthy controls were treated with various JAKi classes, before stimulation with Toll-like receptor (TLR)-4 (lipopolysaccharide [LPS]) or TLR3 (polyinosinic-polycytidylic acid-poly (I:C)) agonists. Conditioned supernatants were used in plasma turbidity assays to evaluate clot formation and lysis dynamics, while bulk RNA sequencing, enzyme-linked immunosorbent assay, and bead-based immunoassays were used to explore immunothrombosis mechanisms. RESULTS: Turbidity analyses showed that conditioned media from PBLs treated with LPS and tofacitinib significantly accelerated clot formation when compared to LPS alone, and this effect was tissue factor pathway dependent and accompanied by elevations in immunothrombotic cytokines, including tumour necrosis factor α, interleukin (IL)-1β, and IL-6. PBLs from patients with active RA exhibited significantly greater immunothrombotic potential compared to those with low disease activity, despite comparable baseline cytokine levels. RNA sequencing analysis revealed significant pathway enrichment in tofacitinib/LPS-treated PBLs, including activation of Nuclear Factor (NF)-κB pathways, increased tissue factor expression, and reduced levels of anticoagulant factors such as protein S. Pharmacological inhibition assays with 5 JAK therapies suggested that JAK1/tyrosine kinase 2-dependent effect underscored increased thrombosis but selective JAK3 inhibition did not reproduce the prothrombotic effects. Finally, patients with RA with JAK-associated pulmonary embolism showed interstitial changes compatible with immunothrombosis in 4/6 (67%). CONCLUSIONS: Immunothrombosis offers a novel explanation for JAKi-associated VTE in RA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidThrombophiliaJanus Kinase InhibitorsVenous ThromboembolismHumansMaleFemaleMiddle AgedPyrimidinesCytokinesCase-Control StudiesPyrrolesLipopolysaccharidesLeukocytesAdultAgedToll-Like Receptor 4Poly I-CPiperidines

Substanzen

Janus Kinase InhibitorsPyrimidinesCytokinesPyrrolesLipopolysaccharidestofacitinibToll-Like Receptor 4Poly I-CPiperidines

Autor:innen und Institutionen

  • Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
  • Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
  • Department of Discovery and Translational Science, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.
  • Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti (HEMORIO), Rio de Janeiro, RJ, Brazil; Faculdade de Medicina da Universidade de São Paulo (FMUSP), Sao Paulo, SP, Brazil.
  • Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Leeds Institute of Medical Research, University of Leeds, Leeds, UK.
  • Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Leeds Teaching Hospitals NHS Trust, Leeds, UK.

Förderung

  • Leeds Biomedical Research Centre

Zitieren

APA

David, P., Macleod, T., Altaie, A., Shi, Y., Abacar, K., Giryes, S., Santos, G. M., Ganguly, P., Harland, M., Wong, C., Scarsbrook, A., Emery, P., Mankia, K., Dass, S., Di Matteo, A., Saleem, B., Duval, C., Ariëns, R., & McGonagle, D. (2026). Augmentation of immunothrombosis as a key mechanism underlying JAK inhibition associated hypercoagulability in rheumatoid arthritis. Annals of the Rheumatic Diseases. https://doi.org/10.1016/j.ard.2025.09.002

Vancouver

David P, Macleod T, Altaie A, Shi Y, Abacar K, Giryes S, et al. Augmentation of immunothrombosis as a key mechanism underlying JAK inhibition associated hypercoagulability in rheumatoid arthritis. Annals of the Rheumatic Diseases. 2026. doi:10.1016/j.ard.2025.09.002

BibTeX
@article{David2026,
  author = {David, Paula and Macleod, Tom and Altaie, Ala and Shi, Yu and Abacar, Kerem and Giryes, Sami and Santos, Gabrielle de Mello and Ganguly, Payal and Harland, Mark and Wong, Chi and Scarsbrook, Andrew and Emery, Paul and Mankia, Kulveer and Dass, Shouvik and Di Matteo, Andrea and Saleem, Benazir and Duval, Cédric and Ariëns, Robert and McGonagle, Dennis},
  title = {Augmentation of immunothrombosis as a key mechanism underlying JAK inhibition associated hypercoagulability in rheumatoid arthritis},
  journal = {Annals of the Rheumatic Diseases},
  year = {2026},
  doi = {10.1016/j.ard.2025.09.002}
}
Kostenlos starten →